House Antidepressants Hearing To Include Six FDA Witnesses
This article was originally published in The Pink Sheet Daily
Executive Summary
House Energy & Commerce/Oversight Subcommittee hearing Sept. 23 will address FDA’s review of pediatric antidepressant data and is structured to pit the testimony of FDA Epidemiologist Andrew Mosholder against other agency officials.
You may also be interested in...
FDA Psychiatry Division To Be Headed By Laughren Under Restructuring Plan
Neuropharmacological reviewer Laughren will head FDA's psychiatric drug reviews after the division is spun off under the Office of New Drugs reorganization. Laughren's appointment is one of few top-level promotions under the restructuring effort.
FDA Psychiatry Division To Be Headed By Laughren Under Restructuring Plan
Neuropharmacological reviewer Laughren will head FDA's psychiatric drug reviews after the division is spun off under the Office of New Drugs reorganization. Laughren's appointment is one of few top-level promotions under the restructuring effort.
FDA Sought To Suppress Vioxx Safety Data, Sen. Grassley Says
Based upon Finance Committee investigators’ interview with FDA Office of Drug Safety’s David Graham, Grassley maintains the agency delayed presentation of a study that found an increased cardiovascular risk associated with Vioxx.